MARKET

CRMD

CRMD

CORMEDIX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.24
+0.09
+1.10%
Opening 13:25 05/11 EDT
OPEN
7.93
PREV CLOSE
8.15
HIGH
8.32
LOW
7.83
VOLUME
102.43K
TURNOVER
--
52 WEEK HIGH
18.80
52 WEEK LOW
3.470
MARKET CAP
313.32M
P/E (TTM)
-10.7194
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 3d ago
CorMedix Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for ...
GlobeNewswire · 6d ago
CorMedix (CRMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 05/03 19:55
CorMedix Inc. to Participate at the 7th Annual Truist Securities Life Sciences Summit
BERKELEY HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, tod...
GlobeNewswire · 04/28 12:30
10 “Strong Buy” Healthcare Stocks With Over 100% Upside Potential According to Top Analysts
TipRanks.com · 04/27 13:58
Cormedix (CRMD) Received its Third Buy in a Row
After Truist Financial and JMP Securities gave Cormedix (NASDAQ: CRMD) a Buy rating last month, the company received another Buy, this time from Needham.
SmarterAnalyst · 04/15 15:15
8-K: CorMedix Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/15 14:46
Mid-Afternoon Market Update: Dow Gains Over 100 Points; Bed Bath & Beyond Shares Plummet
Toward the end of trading Wednesday, the Dow traded up 0.33% to 33,787.64 while the NASDAQ fell 0.62% to 13,908.97. The S&P also fell, dropping 0.22% to 4,132.40.
Benzinga · 04/14 18:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRMD. Analyze the recent business situations of CORMEDIX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRMD stock price target is 20.90 with a high estimate of 31.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 91
Institutional Holdings: 10.42M
% Owned: 27.39%
Shares Outstanding: 38.02M
TypeInstitutionsShares
Increased
29
811.37K
New
12
378.27K
Decreased
12
34.35K
Sold Out
8
221.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.56%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Independent Director
Myron Kaplan
Chief Executive Officer/Chief Accounting Officer/Director
Khoso Baluch
Chief Financial Officer/Executive Vice President
Matt David
Chief Financial Officer/Executive Vice President
Matthew David
Executive Vice President/General Counsel
Phoebe Mounts
Executive Vice President
John Armstrong
Executive Vice President
Elizabeth Masson
Director
Paulo Costa
Director
Gregory Duncan
Independent Director
Janet Dillione
Independent Director
Alan Dunton
Independent Director
Steven Lefkowitz
No Data
  • All
  • Financials
  • Insiders
More
About CRMD
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Webull offers kinds of CorMedix Inc. stock information, including NASDAQ:CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.